预约演示
更新于：2026-08-12
Indacaterol Acetate/Glycopyrronium Bromide/ Mometasone Furoate
醋酸茚达特罗/格隆溴铵/莫米松糠酸酯
更新于：2026-08-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2020-06-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C28H32N2O7 |
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N |
CAS号753498-25-8 |
查看全部结构式(3)
关联
17
项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的临床试验NCT05776927
A Double-dummy, Double-blind, Randomized, Active Controlled, Two-way Cross-over Study With 12 Week Treatment Duration Period, to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
CTR20261101
茚达格莫吸入粉雾剂（II）在中国健康试验参与者中随机、开放、两制剂、单次给药、两周期、交叉空腹状态下的生物等效性试验
CTR20253369
茚达格莫吸入粉雾剂（Ⅱ）（150 μg /50 μg/160 μg）在中国健康受试者中随机、开放、两制剂、单次给药、双周期、交叉空腹状态下的生物等效性试验
100 项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的临床结果
登录后查看更多信息
100 项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的转化医学
登录后查看更多信息
100 项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的专利（医药）
登录后查看更多信息
13
项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的文献（医药）2025-12-01CLINICAL THERAPEUTICS
A Novel Metered Dose Inhaler Formulation of Triple-Drug Fixed-Dose Combination of Vilanterol, Glycopyrronium, and Fluticasone Furoate: A Phase III, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety in Indian Patients With Uncontrolled Asthma
Article
作者: Kumar, Deepak ; Panda, Jayanta Kumar ; Pathak, Hardik ; Parmar, Deven ; Jain, Manish Kumar ; Sahoo, Diptikant ; Patel, Chintan ; Kansagra, Kevinkumar ; Koppula, Ravi ; Sheth, Vaishal ; Verma, Sanjay
PURPOSE:
This study aimed to evaluate the efficacy and safety of a fixed-dose combination (FDC) of vilanterol 12.5 µg, glycopyrronium 25 µg, and fluticasone furoate 100 µg (VIL-GLY-FF)-metered dose inhaler (MDI) (developed by M/s. Zydus Healthcare Limited) in comparison with the approved FDC of indacaterol 150 µg, glycopyrronium 50 µg, and mometasone furoate 160 µg (IND-GLY-MF)-dry powder inhaler (DPI) in patients with persistent asthma.
METHODS:
Patients were randomized (1:1) in either the test (VIL-GLY-FF-MDI) or reference (IND-GLY-MF-DPI) group. Fixed-dose combinations were administered once daily for 12 weeks; for VIL-GLY-FF-MDI, patients were instructed to administer TWO actuations at 1 time in a day, doubling the final doses delivered of its components. For IND-GLY-MF-DPI, (Zydus Healthcare Limited, Ahmedabad) patients inhaled 1 capsule via the Respihaler device once daily. The primary objective was to compare the between-group difference in the change in trough forced expiratory volume in 1 second (FEV1) at week 12 from baseline.
FINDINGS:
A total of 256 patients were enrolled. The change in least square mean (SE) in trough FEV1 at week 12 from baseline was 287.15 (18.00) mL and 284.94 (17.93) mL for the test and reference groups, respectively. For a predefined -150 mL noninferiority margin, 2-sided 95% CIs (-47.83 to 52.26 mL) for the difference in the mean change in trough FEV1 (2.21 mL) between the 2 groups reported the noninferiority of VIL-GLY-FF-MDI to IND-GLY-MF-DPI. The test FDC was well tolerated.
IMPLICATIONS:
Efficacy and safety of VIL-GLY-FF-MDI were found to be similar to those of IND-GLY-MF-DPI in Indian patients with persistent asthma. Clinical Trial Registry India identifier: CTRI/2024/01/061230.
2025-11-01The journal of allergy and clinical immunology. Global
Effectiveness of indacaterol/glycopyrronium/mometasone for refractory asthmatic cough after switching from inhaled corticosteroid/long-acting β2-agonist therapy
Article
作者: Saito, Junpei ; Miyao, Naoki ; Kamei, Tadashi ; Ohbayashi, Hiroyuki ; Tochigi, Takao ; Yamagata, Eiji ; Matsuoka, Hirofumi ; Tajiri, Tomoko ; Kiyosue, Arihiro ; Mikami, Toshiaki ; Tsuji, Toshinaga ; Fukushima, Yasushi ; Kanemitsu, Yoshihiro ; Niimi, Akio ; Asamoto, Hitoshi ; Hara, Johsuke
Background:
Cough is a major symptom in poorly or partially controlled asthma, which persists despite treatment, thus impairing quality of life.
Objectives:
The primary objective was to demonstrate the superiority of medium-dose indacaterol, glycopyrronium, and mometasone furoate (IND/GLY/MF) over high-dose inhaled corticosteroids (ICS)/long-acting β2-agonists (LABA) in adult asthma patients with cough refractory to medium-dose ICS/LABA.
Methods:
In this multicenter, randomized, open-label, parallel-group study, 118 patients were randomized to receive either IND/GLY/MF or high-dose ICS/LABA (fluticasone/vilanterol [FF/VI] or budesonide/formoterol [BUD/FM]) for 8 weeks. Efficacy was measured by the Japanese version of the Leicester Cough Questionnaire at week 8. Additional analyses included a visual analog scale, the 6-item Asthma Control Questionnaire, respiratory function, fractional exhaled nitric oxide, and blood eosinophil/neutrophil measurements. Registration: Public clinical trials registry as study jRCTs04122000.
Results:
The change from baseline to week 8 in the total questionnaire score was 1.99 ± 3.48 in the IND/GLY/MF group and 2.50 ± 4.28 in the high-dose ICS/LABA group, with no statistically significant difference between the two groups (P = .5037). However, the change in the total questionnaire score from baseline to week 8 was statistically significant in each treatment group (P < .0001 in the IND/GLY/MF group, P = .0242 in the FF/VI comparator group, and P = .0012 in the BUD/FM comparator group). Fractional exhaled nitric oxide and eosinophil counts significantly decreased in the high-dose ICS/LABA group, while neutrophil counts significantly fell in the IND/GLY/MF group at week 8, by between-group comparison.
Conclusion:
Symptoms improved comparably between medium-dose IND/GLY/MF and high-dose ICS/LABA combinations, although no superiority could be demonstrated. Medium-dose IND/GLY/MF may be an alternative to high-dose ICS/LABA.
2024-07-01Respiratory Investigation
Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan
Article
作者: Kieran J. Rothnie ; Stephen G. Noorduyn ; Toru Oga ; Gema Requena ; Masao Yarita ; Chifuku Mita ; Risako Ito ; Liza Yuanita
BACKGROUND:
Real-world data assessing characteristics of patients with asthma initiating inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) triple therapy in Japan are limited.
METHODS:
Descriptive, observational study of patients with asthma aged ≥15 years newly initiating single- or multiple-inhaler triple therapy (SITT: fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI], SITT: indacaterol/glycopyrronium bromide/mometasone furoate [IND/GLY/MF] or MITT) or ICS/LABA using JMDC/Medical Data Vision (MDV) health insurance databases from February 2021-February 2022 (first prescription date: index date). Patients were assigned to three non-mutually exclusive cohorts: A) new FF/UMEC/VI initiators; B) new FF/UMEC/VI, IND/GLY/MF, or MITT initiators; C) new FF/UMEC/VI, IND/GLY/MF, MITT or ICS/LABA initiators as initial maintenance therapy (IMT). Patient characteristics were assessed descriptively for 12-months pre-treatment initiation (baseline period).
RESULTS:
Cohort A: among new FF/UMEC/VI initiators, 12.8% and 0.1% (JMDC) and 21.7% and 0.9% (MDV) of patients had ≥1 moderate and severe exacerbation; 52.0% (JMDC) and 79.2% (MDV) had ICS/LABA use. Cohort B: most patients initiated FF/UMEC/VI and IND/GLY/MF over MITT (JMDC: 91.3% vs 8.7%; MDV: 67.8% vs 32.2%), with fewer exacerbations and lower rescue medication use. Cohort C: a greater proportion of FF/UMEC/VI initiators as IMT experienced a moderate exacerbation at index versus ICS/LABA initiators as IMT (JMDC: 17.8% vs 10.7%; MDV: 8.0% vs 5.1%).
CONCLUSIONS:
Patient characteristics were generally similar between treatment groups; SITT initiators had fewer exacerbations and lower rescue medication use than MITT initiators, represented by the greater proportion of IMT among SITT versus MITT initiators. Physicians may have prescribed triple over dual therapy as IMT in response to an exacerbation.
23
项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的新闻（医药）2026-07-24
2026-07-02
100 项与 醋酸茚达特罗/格隆溴铵/莫米松糠酸酯 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 哮喘 | 日本 | 2020-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 过敏性哮喘 | 临床3期 | 荷兰 | 2020-09-10 | |
| 持续性哮喘 | 临床3期 | 日本 | 2017-04-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
Pubmed 人工标引  | 临床3期 | 145 | 獵艱鏇衊製糧繭遞製鏇(鹽餘選夢膚蓋衊餘襯範) = 膚鑰糧鏇餘鹹顧艱鹽淵 鹽襯襯膚憲艱壓憲襯壓 (襯艱壓壓觸鑰夢夢簾觸 ) 更多 | 积极 | 2022-05-30 | ||
獵艱鏇衊製糧繭遞製鏇(鹽餘選夢膚蓋衊餘襯範) = 膚襯鬱廠夢鑰網積繭鑰 鹽襯襯膚憲艱壓憲襯壓 (襯艱壓壓觸鑰夢夢簾觸 ) 更多 | |||||||
N/A | 135 | 糧淵鹽選鹽夢衊醖憲網(艱窪艱製製鏇淵壓蓋襯) = 淵膚壓廠顧齋膚簾齋鹹 遞衊願繭齋鏇襯鹹窪鬱 (製襯繭築簾鹽鹹夢觸艱 ) | - | 2021-09-05 | |||
临床1期 | - | 24 | IND/GLY/MF medium-dose | 衊艱鏇遞製醖願鹹壓鹹(淵夢艱鹽網衊願繭淵遞) = 積夢簾鏇齋窪網製壓衊 製鑰艱範壓觸糧鬱糧遞 (壓鬱廠製衊餘衊製壓顧 ) 更多 | - | 2021-02-01 | |
IND/GLY/MF high-dose | 衊艱鏇遞製醖願鹹壓鹹(淵夢艱鹽網衊願繭淵遞) = 淵觸蓋選簾廠製鹹製鏇 製鑰艱範壓觸糧鬱糧遞 (壓鬱廠製衊餘衊製壓顧 ) 更多 | ||||||
临床3期 | 1,426 | (QVM149 150/50/80 μg) | 膚襯衊網廠窪餘選衊製(鬱積鹽廠艱鹽膚遞鬱糧) = 糧繭構觸繭醖淵壓願遞 獵蓋願齋鏇餘選醖遞繭 (窪鹽艱願膚憲繭鏇齋餘, 0.070) 更多 | - | 2020-10-14 | ||
(QVM149 150/50/160 μg) | 膚襯衊網廠窪餘選衊製(鬱積鹽廠艱鹽膚遞鬱糧) = 夢壓壓範簾鏇觸廠製糧 獵蓋願齋鏇餘選醖遞繭 (窪鹽艱願膚憲繭鏇齋餘, 0.069) 更多 | ||||||
临床3期 | 3,092 | (QVM149 150/50/160 µg o.d.) | 製壓壓襯積蓋鹽醖繭獵(願廠壓鑰醖醖獵糧網艱) = 選窪衊餘艱壓顧積願膚 構獵繭築網夢襯簾簾鬱 (壓蓋範築膚夢積願醖膚, 0.0128) 更多 | - | 2020-07-22 | ||
(QVM149 150/50/80 µg o.d.) | 製壓壓襯積蓋鹽醖繭獵(願廠壓鑰醖醖獵糧網艱) = 廠鹹膚窪積衊齋觸觸觸 構獵繭築網夢襯簾簾鬱 (壓蓋範築膚夢積願醖膚, 0.0129) 更多 | ||||||
临床3期 | 4,851 | Mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) | 廠鹹鏇鹽鏇遞淵壓構衊(膚壓製願糧製網繭簾遞): Δ = 76 (95% CI, 41 ~ 111), P-Value = <0·001 | 积极 | 2020-07-09 | ||
Mometasone furoate and indacaterol acetate (MF-IND) | |||||||
临床3期 | 96 | 遞鹽艱觸範獵淵積壓範 = 鑰醖鏇壓壓糧憲願積鬱 鑰艱獵構衊糧衊糧廠淵 (壓醖憲繭構衊鹹願淵構, 淵選鑰齋衊鹽製憲廠範 ~ 醖簾構衊糧構齋夢積積) 更多 | - | 2020-04-07 | |||
临床2期 | 116 | (QVM149 150/50/160 μg o.d.) | 獵膚艱憲鬱遞繭鑰繭願(範遞構廠醖襯遞醖窪選) = 觸膚憲繭願襯網築積淵 襯築鬱廠餘鬱鬱夢膚遞 (廠積鬱艱範遞淵襯壓簾, 0.0750) 更多 | - | 2019-12-13 | ||
(QVM149 150/50/80 μg o.d.) | 獵膚艱憲鬱遞繭鑰繭願(範遞構廠醖襯遞醖窪選) = 廠壓獵獵願齋蓋廠齋遞 襯築鬱廠餘鬱鬱夢膚遞 (廠積鬱艱範遞淵襯壓簾, 0.0750) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用